Biotech Sector Sees Major Swings on Clinical Trial Results

Investing.com -- Shares of Disc Medicine, Inc. (NASDAQ: IRON) jumped 60% after the company announced overwhelmingly positive topline results from its Phase 3 APOLLO trial. The trial evaluated bitopertin, an investigational treatment for adults and adolescents with erythropoietic protoporphyria (EPP).

The randomized, double-blind trial of 183 global patients met every primary and secondary endpoint, demonstrating statistically significant improvements across all study measures compared to a plac

Investing.com -- Veradermics Inc (NYSE: MANE) shares rose 6.7% in premarket trading Monday after the company announced its oral hair loss drug VDPHL01 met all primary and secondary endpoints in a Phase 3 clinical trial.

The registration-directed Phase 3 trial, Study '304', enrolled 536 male participants with mild-to-moderate pattern hair loss who received either VDPHL01 8.5mg once daily, VDPHL01 8.5mg twice daily, or placebo. VDPHL01 demonstrated increases in target area hair count of 28.6 hair

Investing.com - Jefferies downgraded EyePoint Inc. (NASDAQ:EYPT) to Hold from Buy and cut its price target to $1.00 from $8.00 on Monday. The stock plummeted to $0.45, down 86% from its previous close of $3.14, with shares now trading near their 52-week low and down 84% year-to-date.

The downgrade follows the company’s Phase 3 LUCIA study of Duravyu in wet age-related macular degeneration missing its primary endpoint of best corrected visual acuity non-inferiority to aflibercept. This marks the